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The expression of CD123 can decrease 
with basophil activation: implications for the 
gating strategy of the basophil activation test
Alexandra F. Santos1,2,3,4, Natalia Bécares1,2, Alick Stephens1,2, Victor Turcanu1,2 and Gideon Lack1,2*
Abstract 
Background: Basophil activation test (BAT) reproduces IgE-mediated allergic reactions in vitro and has been used 
as a diagnostic test. Different markers can be used to identify basophils in whole blood and have implications for the 
outcome of the test. We aimed to assess changes in the expression of CD123 and HLA-DR following basophil activa-
tion and to select the best gating strategy for BAT using these markers.
Methods: BAT was performed in whole blood from 116 children. Peanut extract, anti-IgE, anti-FcεRI or formyl-meth-
ionyl-leucyl-phenylalanin (fMLP) was used for stimulation. Surface expression of CD123, HLA-DR, CD63 and CD203c 
was evaluated by flow cytometry.
Results: In some cases, gating on CD123+/HLA-DR− led to the loss-to-analysis of basophils in conditions where 
basophils were activated. Adding CD203c as an identification marker restored the cell number. Basophils remained 
HLA-DR-negative with activation. CD123 expression decreased following stimulation with fMLP (n = 116, p < 0.001), 
anti-IgE (n = 104, p < 0.001) and peanut (n = 42, p < 0.001). The decrease in the mean fluorescence intensity of 
CD123 correlated with the up-regulation of basophil activation markers, CD63 (rs = −0.31, p < 0.001) and CD203c 
(rs = −0.35, p < 0.001). BAT to peanut gating basophils on CD203c+/CD123+/HLA-DR− reduced the false-negatives 
(1 vs. 5 %) and showed a higher diagnostic accuracy compared to using CD123+/HLA-DR− (97 vs. 91 %). CD203c+ 
appeared as an alternative gating strategy allowing two-colour BAT.
Conclusions: Basophils of a subset of patients down-regulate CD123 with activation. The use of CD203c before 
gating on CD123+/HLA-DR− cells or in isolation ensures the identification of the entire basophil population and 
accurate assessment of basophil activation, with important diagnostic implications.
Keywords: Basophil activation test, Peanut allergy, CD123, CD63, CD203c, IL-3
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The basophil activation test (BAT) is a flow cytometry-
based assay that reproduces IgE-mediated allergic reac-
tions in  vitro. Following cell stimulation and activation, 
basophils undergo degranulation with the release of 
histamine, leukotrienes and cytokines, and up-regulate 
the expression of activation markers on their surface, 
such as CD63 and CD203c, which can be measured by 
flow cytometry [1, 2]. CD63 is a lysosomal-associated 
membrane protein (LAMP-3) and is not expressed on 
resting basophils but only after degranulation as the 
granules fuse with the plasma membrane. Its expression 
is bimodal, as only a subset of basophils express CD63, 
therefore it is usually represented as a proportion of posi-
tive cells (i.e. %CD63+ basophils). CD203c is constitu-
tively and specifically expressed on the surface of resting 
basophils, which increases after basophil activation; thus, 
it can be used as an identification as well as an activa-
tion marker [3]. CD203c has been related to piecemeal 
degranulation and CD63 to anaphylactic degranulation 
[4, 5]. The BAT has been used primarily as a research tool 
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and its application for clinical use in the diagnosis and 
monitoring of allergic diseases [6–10], namely following 
immuno-modulatory treatments such as allergen-specific 
immunotherapy [11–13] and omalizumab [14–16], is still 
in development. Our first allergen-specific (peanut) study 
that is clinically validated and based on double-blind-
placebo-controlled-food-challenges (DBPCFC) initially 
established retrospectively diagnostic cut-off values for 
CD63 expression (n  =  104) and verified this prospec-
tively in a second population (n =  65) [6]. In this study 
[6], BAT showed 97 % accuracy in the diagnosis of peanut 
allergy. This enhanced diagnostic performance is in large 
part due to inclusion of CD203c in the gating strategy.
Different cell-surface markers may be preferred for 
the identification of basophils in whole blood. One of 
the commonly used is the combination of CD123 and 
HLA-DR [1, 2]. CD123 is the low affinity subunit of the 
IL-3 receptor and is highly expressed on plasmocytoid 
dendritic cells and basophils, and in low levels on mono-
cytes, eosinophils, myeloid dendritic cells and hemato-
logic progenitor cells. While eosinophils can be excluded 
by side-scatter, additional staining with anti-HLA-DR 
discriminates between HLA-DR-negative basophils 
and HLA-DR-positive dendritic cells and monocytes. 
To exclude hematologic progenitor cells, an additional 
marker specific for basophils such as CD203c could be 
used. In previous studies, the expression of CD123 and 
HLA-DR were shown to be stable with the atopic sta-
tus of patients and following basophil activation [2, 17]. 
However, stimulation of the IL-3 receptor by IL-3 can 
increase the baseline expression of CD203c and pos-
sibly CD63 and maximise the up-regulation of CD63 
upon basophil activation [4, 18]. Therefore, we hypoth-
esized that CD123 expression could change in response 
to basophil activation. With increasing attention given 
to basophils in the coordination of adaptive immune 
responses and their possible role in antigen presentation 
[19–21], we considered that there could be an increase in 
the expression of HLA-DR by basophils following activa-
tion by allergen or other stimulants. Given the important 
implications for the gating strategy to be adopted for BAT 
in future studies, we sought to determine whether the 
expression of CD123 and HLA-DR remained unchanged 
with basophil activation and to select the best gating 
strategy using these markers.
Methods
Study population
Results of BAT to peanut performed in children attend-
ing our Pediatric Allergy clinic, aged from 5  months to 
17  years, performed using the same methodology as 
part of two clinical studies [6, 10] were analyzed. Peanut 
allergy was diagnosed based on a positive oral peanut 
challenge or the combination of a recent clear history 
of one or more systemic reactions to peanut and a weal 
diameter on skin prick testing (SPT) ≥8  mm and/or 
serum peanut-specific IgE ≥15 KUA/l [22]. Peanut-toler-
ance was defined by a negative oral peanut challenge or 
the ability to eat an age-appropriate quantity of peanut 
regularly (as defined by a validated food-frequency ques-
tionnaire [23]) without developing any allergic symp-
toms. Ethical approval was obtained from the South East 
London Research Ethics Committee 2 and parents of all 
children signed written informed consent.
Whole blood basophil activation test
Heparinized whole blood (100  µl) was stimulated for 
30 min at 37 °C with peanut extract (0.1; 1; 10; 100; 1000 
and 10,000  ng/ml, ALK Abelló, Horsholm, Denmark) 
diluted in Rosewell Park Memorial Institute (RPMI, 
GIBCO, Paisley, UK). Polyclonal goat IgG anti-human 
IgE (1  µg/ml, Sigma-Aldrich, Poole, UK) and monoclo-
nal mouse anti-human FcɛRI (2.5  µg/ml, Ebioscience, 
San Diego, CA, USA) were used as IgE-mediated positive 
controls. Formyl-methionyl-leucyl-phenylalanine (1  µM, 
fMLP, Sigma-Aldrich) was used as a non-IgE-mediated 
positive control (as it acts via a G-protein-coupled recep-
tor (FPR-1) that activates MAPK pathways and phos-
pholipase C bypassing part of the signalling pathway 
downstream the IgE receptor FcεRI). RPMI alone was 
used as a negative control. The reaction was stopped by 
adding cold ethylenediaminetetraacetic acid. Prior to 
erythrocyte lysis with BD Pharmlyse (BD Biosciences, 
San Jose, CA, USA), cells were stained with anti-CD123-
fluorescein isothiocyanate (FITC) (Ebioscience), anti-
CD203c-phyco-erythrin (PE), anti-HLA-DR-peridinin 
chlorophyll protein (PerCP) and anti-CD63-allophy-
cocyanin (APC) (Biolegend, San Diego, CA, USA) for 
30 min. In selected experiments, anti-CD14-PECy7, anti-
CD3-pacific blue (PB), anti-CD19-PB, anti-CD41-PB and 
anti-CD56-PB (Biolegend) were additionally used. The 
surface expression of these markers was evaluated using 
FACS CantoII with FACSDiva software (BD Biosciences, 
San Jose, CA, USA). Data was analysed with FlowJo soft-
ware version 7.6.1 (TreeStar, Ashland, OR, USA).
Basophil activation was expressed as a proportion 
of CD63+ basophils, corrected for the negative con-
trol, and as a ratio of the MFI of CD203c-PE of stimu-
lated to unstimulated basophils, the stimulation index 
of CD203c (SI CD203c). The variation of CD123 was 
defined as the proportion of the difference between the 
MFI of CD123-FITC of the negative control and of the 
stimulated cells and the MFI of CD123-FITC of the nega-
tive control, and was calculated using the formula (MFI 
CD123-FITC of negative control − MFI CD123-FITC of 
stimulated cells)/MFI CD123-FITC of negative control. 
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When assessing basophil activation induced by anti-IgE 
(n  =  104), patients with non-responder basophils, i.e. 
basophils which did not respond to any IgE-mediated 
stimulants but only to fMLP, were excluded. When eval-
uating the response to peanut, peanut allergic patients 
with responding-basophils were considered (n = 42). In 
the data analysis, when only one concentration of peanut 
extract was used, 100 ng/ml was selected unless indicated 
otherwise.
Statistical analysis
Qualitative variables were represented as number of 
patients and percentage (taking into account the miss-
ing values) and groups were compared using the Fisher’s 
exact test or Chi square test, as appropriate. Continuous 
variables were represented as median and range and were 
compared using the Mann–Whitney U test or Kruskall–
Wallis test, as appropriate. Wilcoxon-signed rank test was 
used to compare samples before and after stimulation.
For receiver-operating characteristic (ROC) curve anal-
ysis, the performance of the average percentage of CD63-
positive basophils at 10 and 100 ng/ml of peanut extract 
determined using different gating strategies was evalu-
ated against the patients’ allergic status to peanut, i.e. in 
relation to allergy versus tolerance.
All statistical analyses were performed with SPSS 20.0 
for Windows. Significance was determined using a two-
sided α level of 0.05.
Results
Gating on basophils using CD123 and HLA‑DR led to the 
loss of cells
Identifying basophils with CD123 and HLA-DR 
(Fig.  1a–d) led to the loss to analysis of cells particu-
larly in conditions where basophils were activated. The 
baseline number of unstimulated basophils was variable 
(median  =  1721, IQR  =  1225–2184) but comparable 
between atopic and non atopic patients (p = 0.444) and 
between peanut allergic and peanut tolerant children 
(p  =  0.739). Following basophil stimulation with fMLP 
(p = 0.012) and anti-IgE (p = 0.005), the number of baso-
phils was significantly reduced compared to baseline 
(Table 1).
Of note, if only patients with non-responder basophils 
were considered (n = 12), the change in basophil number 
was significant after fMLP stimulation (p  =  0.004) but 
not after anti-IgE stimulation (p = 0.099), suggesting that 
the reduction in cell number was dependent on baso-
phil activation. Considering anti-IgE stimulation, 14 % of 
patients showed more than 25 % decrease in the number 
of basophils compared to the negative control (Fig. 2).
In 27  % of patients, this number decreased to below 
1000 basophils (the minimum number of cells usually 
required for BAT). Selecting peanut allergic patients, a 
trend was seen toward a reduction in the basophil num-
ber after stimulation with 1000  ng/ml of peanut extract 
compared to the negative control (n = 42, p = 0.081). As 
the starting volume of blood, and thus the starting num-
ber of cells, was similar in all experimental conditions, 
we hypothesized that the expression of the identification 
markers, CD123 and/or HLA-DR, changed with basophil 
activation.
CD123 is down‑regulated with basophil activation
To evaluate the changes in the expression of CD123 and 
HLA-DR on the surface of basophils, we used CD203c 
to gate on the basophil population (Fig. 1a–g). The base-
line MFI of CD123-FITC was variable between patients 
(median  =  1082, IQR  =  98–1549) but comparable 
between atopic and non-atopic children (p = 0.153) and 
between peanut allergic and peanut tolerant patients 
(p  =  0.826). Down-regulation of CD123 by basophils 
was seen following stimulation with fMLP (n  =  116, 
p  <  0.001), anti-IgE (n  =  104, p  <  0.001) and peanut 
extract (n  =  42 peanut allergic patients, p  <  0.001)—
Table 1 and Fig. 3a. In 92.3 % of patients, anti-IgE stim-
ulation led to a decrease in the MFI of CD123-FITC 
compared to the negative control: in 38.5 less than 25 % 
decrease, in 26.9  % between 25 and 50  % decrease, in 
13.5 % between 50 and 75 % decrease and in 13.5 more 
than  75  % decrease (Fig.  4a). The down-regulation of 
CD123 expression on the surface of basophils stimu-
lated by fMLP and by anti-IgE was correlated (rs = 0.723, 
p < 0.001), suggesting this phenomenon happened in the 
same patients with different stimulants. The decrease in 
CD123 expression with anti-IgE stimulation was similar 
between atopic and non atopic (p = 0.828) and between 
peanut allergic and peanut tolerant children (p = 0.431). 
The expression of CD123 was stable when basophils 
were not activated—for example, after stimulation with 
peanut in peanut tolerant patients (p  =  0.658) or after 
stimulation with anti-IgE in non-responders’ basophils 
(p = 0.083), while down-regulation was still observed in 
this subgroup after stimulation with fMLP (p = 0.006).
Basophils were HLA-DR-negative and were distinct 
from the CD123+ HLA-DR+ population of plasmacy-
toid dendritic cells. Following basophil activation, the 
HLA-DR expression did not increase and remained dis-
tinct from HLA-DR+ cells.
Decrease in CD123 is correlated with the up‑regulation 
of CD63 and CD203c
Taken together the previous observations indicate 
that the down-regulation of CD123 by basophils is an 
activation-dependent phenomenon. A weak statistically 
significant correlation was observed between the 
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decrease in the MFI of CD123 and the up-regulation 
of basophil activation markers after stimulation with 
anti-IgE (Fig.  4b) as measured by the stimulation index 
of CD203c (rs = −0.35, p < 0.001) or by the percentage 
of CD63-positive basophils (rs  =  −0.31, p  <  0.001), 
suggesting that the basophils that down-regulate CD123 
the most are also the ones that express more CD63 and 
CD203c. The correlations between changes in the MFI of 
CD123-FITC and in the percentage of CD63+ basophils 
or the SI of CD203c following stimulation with fMLP 
(−0.191, p =  0.04 and −0.223, p =  0.016, respectively) 
and following stimulation with peanut extract (−0.229, 
p =  0.145 and −0.31, p =  0.051, respectively) were less 
strong.
Fig. 1 Basophils were identified in whole blood in the lymphocyte-monocyte area (a) as SSClow/CD123+/HLA-DR− (b, c) or as SSClow/CD203c+ 
(e) or as SSClow/CD203c+/CD123+/HLA-DR− (e, f) cells. CD63 expression was assessed in basophils identified as SSClow/CD123+/HLA-DR− (d) or 
SSClow/CD203c+/CD123+/HLA-DR− (g).
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Additional use of CD203c prevented the loss‑to‑analysis 
of activated basophils
The down-regulation of CD123 with basophil activa-
tion has important implications in gating strategies that 
depend on CD123. Identifying basophils using CD123 
and HLA-DR led to the loss-to-analysis of basophils, par-
ticularly of the ones with higher expression of the activa-
tion markers CD63 and CD203c, and thus leading to an 
underestimation of basophil activation (Table 2; Fig. 5a). 
Adding CD203c as an identification marker restored the 
cell number, regardless of the basophil activation status 
and allowed to include the basophils that were activated 
the most in the analysis, improving the outcome of the 
test (Table 2; Fig. 5b). The expression of CD203c remained 
stable or increased following basophil activation, allowing 
a good separation from the remaining blood cells (Fig. 3b).
Selecting the optimal gating strategy using CD203c
In order to select the best gating strategy using the avail-
able markers, we compared the results of the BAT follow-
ing the identification of basophils as SSClow/CD203c+ 
cells, as SSClow/CD123+/HLA-DR− cells or as SSClow/
CD203c+/CD123+/HLA-DR−. To combine the three 
identification markers to gate on basophils, we first 
selected the SSClow/CD203c+ cells and then gated on 
the plot CD123/HLA-DR following the contour of the 
cell population of interest, including CD123low as well as 
CD123high cells, all HLA-DR− (Fig. 1f ).
The gating strategy using CD203c+/CD123+/HLA-
DR− proved superior to CD123+/HLA-DR− and similar 
to what was observed for gating on CD203c+ cells alone 
(Table  2). The combination of the three markers was 
superior to CD203c+ in the subgroup of peanut allergic 
patients improving the detection of basophil activation 
(Table 2, borderline non-significant p values for %CD63+ 
Table 1 Number of  basophils (gated as  SSClow/CD123+/
HLA-DR− cells) and  expression of  CD123 on  the surface 
of basophils (gated as SSClow/CD203c+ cells) as measured 
by MFI of CD123-FITC in different stimulation conditions
Median (inter-quartile range) is represented. p value refers to the comparison of 
post-stimulation conditions with the negative control
Stimulant n Pre‑stimulation Post‑stimulation p value
Number of basophils
 fMLP 116 1722 (1226, 2184) 1572 (1037, 2100) 0.012
 Anti-IgE 104 1722 (1221, 2191) 1414 (972, 1995) 0.005
 Peanut extract 42 1732 (1212, 2174) 1514 (914, 2041) 0.134
MFI of CD123-FITC
 fMLP 116 1082 (98, 1549) 514 (75, 1020) <0.001
 Anti-IgE 104 1081 (95, 1549) 495 (60, 1111) <0.001
 Peanut extract 42 1172 (80–2058) 293 (40, 1244) <0.001
Fig. 2 Variation in the number of identified basophils following 
anti-IgE stimulation compared to the negative control (n = 104). Vari-
ation was calculated as (number of identified basophils pre-stimula-
tion − number of identified basophils post-stimulation)/number of 
identified basophils pre-stimulation
Fig. 3 Changes in the MFI of CD123-FITC (a) and in the MFI of CD203c-PE (b), following stimulation with 100 ng/ml of peanut extract (n = 42 
peanut allergic patients)
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basophils, SI CD203c and MFI of CD203c) and in 
patients with a subset of CD203c+/HLA-DR+ cells thus 
avoiding contamination with HLA-DR+ cells. However, 
in the majority of patients, the gating strategies SSClow/
CD203c+ and SSClow/CD203c+/CD123+/HLA-DR− 
were comparable. SSClow/CD203c+ could be used as an 
alternative gating strategy in a two-colour BAT.
In additional experiments (n  =  10) using antibodies 
anti-CD14, anti-CD3, anti-CD19, anti-CD41 and in six 
of these experiments also anti-CD56, there was no con-
tamination of the gating strategy using SSClow/CD203c+/
CD123+/HLA-DR− with other immune cells nor did 
they express CD203c. Only in one patient, CD14+ cells 
were also CD203low and HLA-DR+. In the PB-positive 
(PB+) population, there was a minor expression of CD63, 
possibly by CD41+ platelets, but this population was 
gated out as it did neither express CD123 nor CD203c, 
and CD63 expression remained stable with activation 
(data not shown).
Gating strategy of BAT has important diagnostic 
implications
The diagnostic performance of BAT gating on SSClow/
CD203c+/CD123+/HLA-DR− was superior to the one 
using SSClow/CD123+/HLA-DR− with a larger area 
under the ROC curve (Fig. 6). The optimal cut-off based 
on the ROC curve generated using the latter gating strat-
egy resulted in a 91 % diagnostic accuracy with 5 % false-
negatives and 3 % false positives (Table 3). Adopting the 
SSClow/CD203c+/CD123+/HLA-DR− gating strategy 
resulted in a diagnostic accuracy of 97 %, as we recently 
reported [6], with 1  % false-negatives and 2  % false-
positives. Unusually, this methodological improvement 
resulted in both enhanced sensitivity and specificity of 
BAT in the diagnosis of peanut allergy. Figure 5 shows an 
example of a patient that would be considered false nega-
tive if gating was confined to CD123+/HLADR− cells. 
Furthermore, using this gating strategy, 15 % of patients 
showed <500 basophils in at least one condition and thus 
BAT would be uninterpretable.
Discussion
BAT can be used to diagnose allergic disease and to 
study the underlying immunological mechanisms. The 
methodology of identification of basophils has important 
consequences for the outcome of the test. In this study, 
we showed that CD123 is down-regulated with basophil 
activation and gating strategies that depend solely on this 
marker lead to the loss-to-analysis of activated basophils 
and to the underestimation of basophil activation. Using 
CD203c in addition to CD123/HLA-DR or in isolation 
proved superior to gating on CD123/HLA-DR, reducing 
the number of false-negatives and false-positives and 
improving the diagnostic accuracy from 91 to 97  %. 
When BAT is used as an allergy test, the gating strategy 
adopted has diagnostic implications in the assessment 
of individual patients. Basophils have been identified 
with CD123 and HLA-DR in previous studies, using 
flow cytometry and other techniques [24], and CD123 
expression was reported to be stable with the atopic status 
of the patient and following basophil activation, although 
no direct comparisons were made [2, 17, 25]. In our study, 
the MFI of CD123-FITC was comparable between atopic 
and non atopic patients, but there was a decrease in the 
MFI of CD123-FITC with basophil activation. This is in 
contrast to previous studies [2, 17, 25] and is probably 
related to differences in the study population (e.g. adults 
vs. children), in the disease models studied (e.g. patients 
with respiratory vs. food allergies) and in the study 
design (e.g. basophils stimulated with allergen in  vivo 
vs. in  vitro, which can have different kinetics). We do 
not believe compensation played a role in the observed 
Fig. 4 Down-regulation of CD123 expression with basophil activa-
tion. a Change in the MFI of CD123-FITC on the surface of basophils 
following anti-IgE stimulation. b Correlation between decrease in 
CD123 and up-regulation of CD63 on the surface of basophils
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changes as this phenomenon only happened in a subset 
of patients and in other patients the expression of CD123 
was stable regardless of the increase in the expression of 
CD63 and CD203c. Furthermore, while the spectrum of 
CD203c-PE overlapped with CD123-FITC, the spectra of 
CD123-FITC and of CD63-APC did not overlap and we 
performed compensation before running the samples, 
used the same compensation matrix during acquisition of 
all samples for each patient and did not see any differences 
in compensation within the same experiment. Although 
the size and the granularity of basophils change with 
activation and degranulation [5, 26], these modifications 
do not lead to cell loss in the FSC/SSC gate and basophil 
numbers are stable with and without stimulation using 
identification markers such as CD203c. With respect to 
HLA-DR, basophils were HLA-DR-negative and kept 
distinct of HLA-DR-positive cells in all conditions. These 
findings are consistent with previous reports [17] and with 
recent studies that did not confirm a role for basophils in 
antigen-presentation in humans [27, 28].
The expression of CD123 being dependent on basophil 
activation raises the question as to whether CD123 can 
be used as a basophil activation marker. However, this 
phenomenon is significant in only a subset of patients 
and the dose–response with increasing concentrations 
of the stimulant is subtle; thus, CD123 does not seem to 
offer any advantage to the existing activation markers, 
such as CD63 and CD203c.
The combination of the three identification markers, 
CD203c/CD123/HLA-DR, proved superior to using 
CD123/HLA-DR. We compared the diagnostic 
performance of BAT to peanut identifying basophils as 
CD123+/HLA-DR− cells and as CD203c+/CD123+/
HLA-DR− cells and the latter resulted in a greater area 
under the ROC curve (0.96 vs. 0.99) and improved 
diagnostic accuracy (91 vs. 97 %). Furthermore, if we took 
into consideration a minimum number of basophils as 
exclusion criteria, 15  % of patients would be inevaluable 
using CD123+/HLADR−. The consequences of the gating 
strategy adopted are clinically relevant as the purpose of 
the BAT is to diagnose peanut allergy in individual patients. 
An example is illustrated in Fig.  5, where with basophils 
gated as CD123+/HLA-DR−, BAT would be considered 
negative at the diagnostic concentration of 100 ng/ml but 
in fact it was clearly positive when basophils were selected 
using the three markers’ strategy. This would be a false-
negative with potential serious consequences, as it could 
lead to liberalization of peanut consumption with the risk 
Table 2 Comparison of different strategies to gate on basophils
Median and inter-quartile range are represented. Medians were compared between the three groups using Kruskall–Wallis test and between two groups using Mann–
Whitney U test
a n = 116
b n = 104 (non-responders were excluded)
c n = 42 (peanut allergic)
1 CD123+/HLA-DR− versus CD203c+
2 CD203c+ versus CD203c+/CD123+/HLA-DR−
3 CD123+/HLA-DR− versus CD203c+/CD123+/HLA-DR−
Parameters Stimulants CD123+ HLA‑DR− CD203c+ CD203c+  
CD123+ 
 HLA‑DR−
Overall  
p value
p value1 p value2 p value3
Number of  
basophils
Negative controla 1722 (1226, 2184) 1782 (1334–2239) 1697 (1268–2134) 0.635 0.390 0.436 0.908
Anti-IgEb 1414 (972–1995) 2156 (1620–3097) 1939 (1452–2877) <0.001 <0.001 0.06 <0.001
fMLPa 1572 (1037, 2100) 2146 (1684–2940) 1891 (1447–2715) <0.001 <0.001 0.084 <0.001
Peanut extractc 1514 (914–2041) 2351 (1748–3062) 2104 (1615–2752) <0.001 <0.001 0.348 0.001
%CD63 +  
basophils
Anti-IgEb 24.8 (10.7, 42.5) 29.4 (17.3–48.9) 32.0 (17.1–53.9) 0.021 0.020 0.809 0.013
fMLPa 28.2 (15.9, 42.3) 41.1 (26.3–53.4) 41.4 (26.9–56.9) <0.001 <0.001 0.644 <0.001
Peanut extractc 32.3 (10.9, 56.2) 41.0 (18.0–56.9) 42.1 (20.0–68.5) 0.185 0.220 0.561 0.074
MFI CD63 Anti-IgEb 104.0 (26.3–195.2) 148 (36, 345) 159.3 (45.4–350.8) 0.019 0.029 0.611 0.009
fMLPa 139 (37, 284) 285 (76, 683) 307 (81, 708) <0.001 <0.001 0.678 <0.001
Peanut extractc 138.4 (24.8–270.7) 190 (37, 513) 202.9 (42.6–567.4) 0.267 0.271 0.629 0.113
SI CD203c Anti-IgEb 2.4 (1.5–3.8) 2.9 (2.0–4.2) 3.2 (2.0–4.6) 0.004 0.028 0.191 0.002
fMLPa 2.3 (1.7–3.1) 2.6 (2.2–3.7) 2.8 (2.2–4.1) <0.001 0.001 0.280 <0.001
Peanut extractc 3.3 (1.8–5.3) 3.8 (2.4–4.8) 4.3 (2.4–5.4) 0.193 0.386 0.260 0.088
MFI CD203c Anti-IgEb 2331 (197–5633) 4833 (254, 9020) 5013 (29–9161) 0.008 0.011 0.677 0.005
fMLPa 2763 (216–5139) 4549 (279, 7961) 4908 (334–8270) 0.001 0.002 0.813 0.001
Peanut extractc 3631.6 (179.4–8491.4) 5312 (206, 11,976) 7012 (236–11,857) 0.173 0.14 0.714 0.083
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of allergic reactions that are potentially severe. The loss-
to-analysis of cells and/or the underestimation of basophil 
activation have important implications for the final 
outcome of the test and thus for the diagnosis of individual 
patients. The same applies to other clinical applications, 
such as monitoring of treatment, and to mechanistic 
experiments. The fact that we detected no contamination 
of the gating with other immune cells suggests that there 
would be no advantage in using a lineage negative antibody 
mixture to exclude other immune cells before gating on the 
CD203c+/CD123+/HLA-DR− cells as basophils.
Identifying basophils with CD203c alone lead to 
comparable outcome in terms of number of basophils 
and basophil activation markers to using CD203c+/
CD123+/HLA-DR− and was also superior to using 
CD123+/HLA-DR−, as represented in Table  2. 
CD203c is a basophil specific marker in whole blood. 
Its constitutive expression is increased in patients with 
atopic eczema and food allergy [29–31], as previously 
described in terms of histamine release [32] suggesting 
it is a marker of underlying basophil activation, possibly 
reflecting ongoing piecemeal degranulation. This 
enhances the separation of CD203c+ basophils from the 
other blood cells in populations of highly atopic children 
[6]. The majority of patients in our study had eczema 
Fig. 5 Gating with CD123/HLA-DR led to the loss-to-analysis of basophils and underestimation of basophil activation. In a representative experi-
ment, basophils were gated as SSClow/CD123bright/HLA-DR− (a) or SSClow/CD203c+/CD123+/HLA-DR− (b). The percentage of CD63+ basophils is 
represented in different conditions: negative control, peanut extract 100 ng/ml and peanut-dose–response curve. Note the bi-exponential display 
[38]
Fig. 6 ROC curve of the average %CD63+ basophils at 10 and 
100 ng/ml of peanut extract using different basophil gating strate-
gies: SSClow/CD203c+/CD123+/HLA-DR− (red), SSClow/CD123+/
HLA-DR− (blue)
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and other food allergies in addition to suspected peanut 
allergy and this represents a population where CD203c 
would be constitutively expressed at a higher level 
than in other children allowing a clear differentiation 
between CD203c+ basophils and other blood cells. 
The conjugation to the bright fluorochrome PE may 
have also contributed to the good identification of cells 
expressing CD203c. SSClow/CD203c+ is an alternative 
basophil identification strategy that has the advantage of 
serving also as an activation marker, enabling BAT to be 
performed as a two-colour (preferred) or even as a single 
colour BAT, which would make BAT easier and less 
expensive to perform.
This is the largest study looking at different strategies 
for identifying basophils using CD123 and its clinical 
implications and it is the first study to report the down-
regulation of CD123 with basophil activation. The 
performance of BAT soon after blood collection and 
the use of live cells for flow cytometry on the same day 
contributed to the quality of the results. However, our 
study population was constituted mostly by highly atopic 
children enrolled in a study examining the use of BAT in 
the diagnosis of peanut allergy [6]. Therefore, our results 
may not apply to other populations, namely of non 
atopic patients or older patients being assessed for other 
conditions such as drug allergy. While assessing changes 
in basophil identification markers, we discovered that in 
a subset of patients basophils down-regulate CD123, the 
low affinity subunit of the IL-3 receptor, with basophil 
activation. This phenomenon seems patient-specific 
rather than specific for atopic or allergic status. In the 
patients where this is observed, the down-regulation 
happens only in conditions where basophils are activated 
and correlates with the degree of activation, as expressed 
by CD63 and CD203c. It is possible that the patients 
who showed higher down-regulation of CD123 after 
basophil activation are the ones with most severe clinical 
reactions but this remains to be confirmed. IL-3 is 
predominantly produced by T cells and is able to induce 
basophils to release histamine and up-regulate CD203c 
and CD63 in the absence of allergen [33, 34]. It can also 
act synergistically with allergen or other stimulants to 
increase basophil activation and histamine release [4, 18, 
33]. The basophil intracellular pathways down-stream 
of the IL-3 and the IgE receptors seem indeed closely 
connected [34]. The response to this priming effect is 
variable between basophil donors and requires different 
concentrations of IL-3 [35]. Some research groups have 
used exogenous IL-3 to prime basophils in the BAT [4, 
18, 36]. However, basophils secrete IL-3 themselves 
in response to IgE-mediated activation for autocrine 
priming, which has been suggested to be a possible 
mechanism underlying the hyper-reactive nature of 
the basophils of allergic patients [37]. We hypothesize 
that the down-regulation of CD123, which is part of the 
IL-3 receptor, could result from a basophil regulatory 
mechanism to avoid further cell activation, but this 
deserves further research.
Conclusions
Basophils down-regulate CD123 with activation in a 
subset of patients and this can have significant deleteri-
ous diagnostic implications. While performing the BAT, 
the use of gating strategies that depend solely on CD123 
may lead to loss-to-analysis of basophils, particularly of 
the ones that highly express CD63 and CD203c, result-
ing in a false-negative outcome for the test. To overcome 
this limitation, additional use of CD203c, both identifica-
tion and activation marker, prevents the loss-to-analysis 
of activated basophils and allows accurate assessment of 
basophil activation and, consequently, a more accurate 
diagnosis of allergy.
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Table 3 Diagnostic accuracy of  the basophil activation 
test to peanut using different gating strategies
The optimal cut-off was determined for the %CD63+ basophils following 
stimulation with 100 ng/ml of peanut extract
PPV positive predictive value, NPV negative predictive value, LR+ positive 
likelihood ratio, LR− negative likelihood ratio
Gating strategy
CD123+ HLADR− CD203c+ CD123+ 
HLADR−
Optimal cut-off 6.8 8.1
AUC ROC for the cut-off 0.91 0.97
Accuracy (%) 91 97
Sensitivity (%) 88 98
Specificity (%) 94 96
PPV (%) 93 95
NPV (%) 90 98
%True positives 40 45
%False positives 3 2
%True negatives 51 52
%False negatives 5 1
LR+ 14.7 24.4
LR− 0.13 0.02
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